Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.

Abstract: A system, method, and air purification device. Air is taken in from an environment into the air purification system. The air is filtered with a primary filter. The filtered air is treated with vacuum ultraviolet radiation in a primary reaction chamber to generate irradiated air. The irradiated air is treated with ultraviolet-C radiation in a secondary reaction chamber to remove ozone and neutralize contaminants to generate purified air. The purified air is emitted back into the environment from the air purification system.

Abstract: An adapter includes a substantially rigid body having a distal portion, a proximal portion, a central opening formed at least in part by an inner wall of the body, and a longitudinal axis extending substantially centrally through the opening. The distal portion includes an annular ring having a top surface and a ridge disposed opposite the top surface, the ridge extending substantially perpendicular to the longitudinal axis. The distal. The adapter also includes a seal configured to form a substantially fluid-tight seal with a surface of a fitting removably attachable to the adapter.

Abstract: In some embodiments, a method of manufacturing includes forming and attaching a first embellishment part onto a substrate composing a clothing article by sintering a thermoplastic powder on the substrate. Sintering may occur at a temperature below a temperature threshold, and sintering may further occur at a pressure below a pressure threshold. The first embellishment part may include all structural components of an entire embellishment. The first embellishment part may be a foundation for a complete embellishment. The method may also include forming a second embellishment part using an additive manufacturing process.

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.

Abstract: A portable power unit includes a base module, a pair of wheels coupled to the base module, and a main core battery disposed in the base module. A portable charger is removably coupled to the base module and includes a charger core battery, a battery receptacle electrically coupled to the charger core battery and configured to mechanically and electrically couple to a battery pack, and a cover movable to selectively allow access to the battery receptacle. The main core battery is electrically couplable with the charger core battery or the battery receptacle.

Abstract: A method of making a golf club head includes the steps of providing a face of a club head, the face having a ball striking surface and a perimeter defining a border of the ball striking surface, providing a golf club head body that includes a crown, a sole, a toe, and a heel, attaching the face to a front portion of the club head body, and milling the ball striking surface and an edge portion of the face to cut a machined surface into the ball striking surface and the edge portion. The milled surface includes a plurality of first grooves located along the ball striking surface and defining a first depth, and a plurality of second grooves located adjacent the perimeter along the edge portion and defining a second depth. The first depth is different than the second depth.

Abstract: In some implementations, an event timeline that includes one or more interactions between a customer and a supplier may be determined. A starting value may be assigned to individual events in the event timeline. A sub-sequence comprising a portion of the event timeline that includes at least one reference event may be selected. A classifier may be used to determine a previous relative value for a previous event that occurred before the reference event and to determine a next relative value for a next event that occurred after the reference event until all events in the event timeline have been processed. The events in the event timeline may be traversed and a monetized value index assigned to individual events in the event timeline.

Abstract: Beacon systems include a beacon including a transmitter, a processor, and a sensor for collecting sensor data, wherein the beacon broadcasts a beacon message comprising informational data based on a value of the sensor data and data regarding a minimum received signal strength for the relevance of the beacon message. The beacon system may include a receiving device, wherein the receiving device comprises a processor and an alarm adapted to be triggered by the beacon message, wherein the processor determines a relevance of the beacon message by comparing the minimum received signal strength for the relevance of the beacon message to an actual received signal strength of the beacon message, wherein, if the actual received signal strength is greater than or equal to the minimum received signal strength, the receiving device is within a range of relevance and the alarm is triggered.

Abstract: Aspects described herein relate to stable cell line for recombinant viral vector (e.g., recombinant adeno associated viral vector) production comprising at least one inducible promoter operatively linked to a heterologous gene that encodes a toxic protein. Methods for making stable cell lines, and methods for viral vector production are further provided herein.

Abstract: Aspects described herein relate to stable cell line for recombinant viral vector (e.g., recombinant adeno associated viral vector) production comprising at least one inducible promoter operatively linked to a heterologous gene that encodes a toxic protein. Methods for making stable cell lines, and methods for viral vector production are further provided herein.

Abstract: Disclosed herein are various optimized nucleic acids encoding the fukutin-related protein (FKRP). Recombinant vectors comprising the optimized nucleic acid (e.g. operatively linked to a muscle specific promoter), such as recombinant adeno-associated virus vectors, for expressing the protein (e.g. in skeletal and cardiac muscle), and therapeutic compositions contains the vectors are also disclosed. Therapeutic methods of administration of the vectors to a subject for the treatment of a subject with a dystroglycanopathy disorder (e.g., limb-girdle muscular dystrophy 2I) are also disclosed.

Abstract: The present invention relates to forskolin-inducible and hypoxia-inducible cis-regulatory elements, promoters and vectors, and methods of their use.

Abstract: Aspects of the disclosure relate to compositions and methods useful for treating neurological diseases and disorders. In some embodiments, the disclosure provides a method for treating a neurological disease or disorder comprising administration of both a viral vector comprising interfering nucleic acids (e.g., artificial miRNAs) and a viral vector comprising a CYP46A1 protein. In some embodiments, the disclosure provides a method for treating Huntington's disease comprising administration of both a viral vector comprising interfering nucleic acids (e.g., artificial miRNAs) targeting the huntingtin gene (HTT) and a viral vector comprising a CYP46A1 protein. In some embodiments, the viral vector comprises a modified viral capsid, such as for preferentially targeting cells in the CNS or PNS.

Abstract: A powered system is disclosed including a power block, an exhaust system configured to receive exhaust gas from the power block, a carbon capture system and a heat recovery system. The exhaust system is configured to couple the carbon capture system to the power block. The carbon capture system is configured to extract CO2 from the exhaust gas. The heat recovery system is configured to receive the extracted CO2 from the carbon capture system for providing heat energy to and from the power plant system.

Abstract: The present invention provides a plurality of synthetic nucleic acid comprising (a) a nucleic acid sequence containing at least one unique regulatory element (URE); wherein the URE comprises at least one regulatory element and a plurality of unique barcodes associated with the at least one regulatory element; and (b) a nucleic acid sequence encoding an transcribable reporter sequence, wherein each barcode is between 12-35 nucleotides in length and have a GC content between 25-65%. URE can be one regulatory element or a combination of regulatory elements. Libraries of expression vectors and plasmids expressing the plurality of synthetic nucleic acids are also provided herein. Additional aspects described herein are methods for identifying the strength of a unique regulatory element in vivo or in vitro using the synthetic nucleic acids or libraries expressing the same.

Abstract: The present invention relates to methods of administration of rAAV vectors in a single administration method comprising a series of sub-administrations of sub-doses of rAAV vectors. The present invention also relates to rAAV vectors comprising cardiac-specific promoters, cardiac-cell specific promoters, multi-cell cardiac specific promoters, and elements thereof. The invention also relates to rAAV vectors, pharmaceutical compositions and uses thereof in methods for treating cardiovascular disease, heart diseases and heart failure in subjects in need thereof.

Abstract: The present invention relates to regulatory nucleic acid sequences, in particular NS-specific promoters, cell specific promoters, multi-cell specific promoters, and elements thereof. The invention also relates to expression constructs, vectors, virions, pharmaceutical compositions and cells comprising such promoters and to methods of their use. The regulatory nucleic acid sequences are of particular utility for gene therapy applications.

Abstract: Disclosed herein are methods, systems, and processes for distributed logging for securing non-repudiable transactions. Credentials, request information, response information, and action items generated and received by a requesting computing system and a responding computing system, and transmitted between the requesting computing system and the responding computing system are separately recorded and stored in a requestor log maintained by the requesting computing system and in a responder log maintained by the responding computing system.